Special Issue "Prodrugs with Peptides as a Carrier for Cancer Treatment"

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 2452

Special Issue Editor

Chapman University School of Pharmacy (CUSP), Harry and Diane Rinker Health Science Campus, Chapman University, Irvine, CA 92618-1908, USA
Interests: antimicrobial peptides; pathogenic bacteria; breast cancer; cancer-targeting agents; cancer diagnostics

Special Issue Information

Dear Colleagues,

Prodrugs with peptides as a carrier, also known as peptide–drug conjugates (PDCs), consist of a targeting peptide covalently conjugated to an anti-cancer drug via a linker. In a PDC, the peptide targets the conjugate to cancer cells sparing non-cancerous healthy cells and tissues. After reaching the cancer site, the linker is cleaved to release the drug that specifically kills the cancer cells. PDCs increase the efficacy and decrease the side effects of an anti-cancer drug by targeting the drug to the cancer site. PDCs have gained recognition in recent years for cancer therapy. Their success has been evident with the recent FDA approval of two PDCs. A PDC lutetium 177 DOTA-TATE, where radionuclide 177Lu is covalently linked to a somatostatin receptor targeting peptide (tyrosine-3 octreotate), was approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in 2018. In addition, a PDC melphalan flufenamide that targets aminopeptidases was approved for the treatment of relapsed or refractory multiple myeloma in 2021. This Special Issue seeks research on “Prodrugs with Peptides as a Carrier for Cancer Treatment” to foster the development of PDCs for cancer treatment.

Prof. Dr. Kamaljit Kaur
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer cell targeting/homing peptide
  • linker chemistry
  • peptide–drug conjugate
  • prodrug
  • therapeutic efficacy
  • targeted drug delivery
  • targeted cancer therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


A Small Peptide Increases Drug Delivery in Human Melanoma Cells
Pharmaceutics 2022, 14(5), 1036; https://doi.org/10.3390/pharmaceutics14051036 - 11 May 2022
Cited by 2 | Viewed by 2177
Melanoma is the most fatal type of skin cancer and is notoriously resistant to chemotherapies. The response of melanoma to current treatments is difficult to predict. To combat these challenges, in this study, we utilize a small peptide to increase drug delivery to [...] Read more.
Melanoma is the most fatal type of skin cancer and is notoriously resistant to chemotherapies. The response of melanoma to current treatments is difficult to predict. To combat these challenges, in this study, we utilize a small peptide to increase drug delivery to melanoma cells. A peptide library array was designed and screened using a peptide array-whole cell binding assay, which identified KK-11 as a novel human melanoma-targeting peptide. The peptide and its D-amino acid substituted analogue (VPWxEPAYQrFL or D-aa KK-11) were synthesized via a solid-phase strategy. Further studies using FITC-labeled KK-11 demonstrated dose-dependent uptake in human melanoma cells. D-aa KK-11 significantly increased the stability of the peptide, with 45.3% remaining detectable after 24 h with human serum incubation. Co-treatment of KK-11 with doxorubicin was found to significantly enhance the cytotoxicity of doxorubicin compared to doxorubicin alone, or sequential KK-11 and doxorubicin treatment. In vivo and ex vivo imaging revealed that D-aa KK-11 distributed to xenografted A375 melanoma tumors as early as 5 min and persisted up to 24 h post tail vein injection. When co-administered, D-aa KK-11 significantly enhanced the anti-tumor activity of a novel nNOS inhibitor (MAC-3-190) in an A375 human melanoma xenograft mouse model compared to MAC-3-190 treatment alone. No apparent systemic toxicities were observed. Taken together, these results suggest that KK-11 may be a promising human melanoma-targeted delivery vector for anti-melanoma cargo. Full article
(This article belongs to the Special Issue Prodrugs with Peptides as a Carrier for Cancer Treatment)
Show Figures

Graphical abstract

Back to TopTop